Novel therapeutic strategies for injured endometrium: intrauterine transplantation of menstrual blood‑derived cells from infertile patients.

Female Animals Humans Endometrium Infertility / prevention & control Uterus Fertility Menstruation
Endometrial infertility Endometrial regeneration Injured endometrium Menstrual blood Mesenchymal stem cell Regenerative therapy

Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
15 10 2023
Historique:
received: 27 11 2022
accepted: 27 09 2023
medline: 23 10 2023
pubmed: 16 10 2023
entrez: 15 10 2023
Statut: epublish

Résumé

Menstrual blood-derived cells show regenerative potential as a mesenchymal stem cell and may therefore be a novel stem cell source of treatment for refractory infertility with injured endometrium. However, there have been few pre-clinical studies using cells from infertile patients, which need to be addressed before establishing an autologous transplantation. Herein, we aimed to investigate the therapeutic capacity of menstrual blood-derived cells from infertile patients on endometrial infertility. We collected menstrual blood-derived cells from volunteers and infertile patients and confirmed their mesenchymal stem cell phenotype by flow cytometry and induction of tri-lineage differentiation. We compared the proliferative and paracrine capacities of these cells. Furthermore, we also investigated the regenerative potential and safety concerns of the intrauterine transplantation of infertile patient-derived cells using a mouse model with mechanically injured endometrium. Menstrual blood-derived cells from both infertile patients and volunteers showed phenotypic characteristics of mesenchymal stem cells. In vitro proliferative and paracrine capacities for wound healing and angiogenesis were equal for both samples. Furthermore, the transplantation of infertile patient-derived cells into uterine horns of the mouse model ameliorated endometrial thickness, prevented fibrosis, and improved fertility outcomes without any apparent complications. In our pre-clinical study, intrauterine transplantation of menstrual blood-derived cells may be a novel and attractive stem cell source for the curative and prophylactic therapy for injured endometrium. Further studies will be warranted for future clinical application.

Sections du résumé

BACKGROUND
Menstrual blood-derived cells show regenerative potential as a mesenchymal stem cell and may therefore be a novel stem cell source of treatment for refractory infertility with injured endometrium. However, there have been few pre-clinical studies using cells from infertile patients, which need to be addressed before establishing an autologous transplantation. Herein, we aimed to investigate the therapeutic capacity of menstrual blood-derived cells from infertile patients on endometrial infertility.
METHODS
We collected menstrual blood-derived cells from volunteers and infertile patients and confirmed their mesenchymal stem cell phenotype by flow cytometry and induction of tri-lineage differentiation. We compared the proliferative and paracrine capacities of these cells. Furthermore, we also investigated the regenerative potential and safety concerns of the intrauterine transplantation of infertile patient-derived cells using a mouse model with mechanically injured endometrium.
RESULTS
Menstrual blood-derived cells from both infertile patients and volunteers showed phenotypic characteristics of mesenchymal stem cells. In vitro proliferative and paracrine capacities for wound healing and angiogenesis were equal for both samples. Furthermore, the transplantation of infertile patient-derived cells into uterine horns of the mouse model ameliorated endometrial thickness, prevented fibrosis, and improved fertility outcomes without any apparent complications.
CONCLUSIONS
In our pre-clinical study, intrauterine transplantation of menstrual blood-derived cells may be a novel and attractive stem cell source for the curative and prophylactic therapy for injured endometrium. Further studies will be warranted for future clinical application.

Identifiants

DOI: 10.1186/s13287-023-03524-z PMID: 37840125 PMC: PMC10577920
pubmed: 37840125
doi: 10.1186/s13287-023-03524-z
pii: 10.1186/s13287-023-03524-z
pmc: PMC10577920
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

297

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Mol Med Rep. 2019 Feb;19(2):813-820
pubmed: 30569163
Sci Rep. 2022 Jan 10;12(1):412
pubmed: 35013490
Reproduction. 2016 Nov;152(5):389-402
pubmed: 27486270
Stem Cells. 2008 Jul;26(7):1695-704
pubmed: 18420831
Int J Gynaecol Obstet. 2013 Dec;123 Suppl 2:S18-24
pubmed: 24119894
Stem Cell Res Ther. 2021 Oct 30;12(1):556
pubmed: 34717746
Nanoscale. 2021 Apr 21;13(15):7334-7347
pubmed: 33889891
Stem Cell Res Ther. 2015 Mar 17;6:32
pubmed: 25889741
Med Sci Monit. 2020 Feb 29;26:e919251
pubmed: 32112554
Reprod Biol Endocrinol. 2017 Mar 3;15(1):14
pubmed: 28253866
Stem Cell Res Ther. 2020 Nov 11;11(1):477
pubmed: 33176882
Hum Reprod Update. 2014 Mar-Apr;20(2):262-78
pubmed: 24082042
J Tissue Eng Regen Med. 2019 Apr;13(4):555-568
pubmed: 30656863
Stem Cell Res Ther. 2021 Jun 5;12(1):328
pubmed: 34090527
Mol Reprod Dev. 2021 Aug;88(8):527-543
pubmed: 34293229
Zygote. 2019 Dec;27(6):367-374
pubmed: 31452481
Cell Mol Life Sci. 2019 Sep;76(17):3323-3348
pubmed: 31055643
Stem Cell Res Ther. 2021 Aug 3;12(1):433
pubmed: 34344458
Clin Biochem. 2018 Dec;62:2-10
pubmed: 29555319
Regen Med. 2020 Jul;15(7):1891-1904
pubmed: 32698666
Stem Cell Res Ther. 2019 Aug 14;10(1):257
pubmed: 31412924
Biomed Pharmacother. 2018 Jun;102:333-343
pubmed: 29571018
Hum Reprod Update. 2015 Jul-Aug;21(4):411-26
pubmed: 25801630
Stem Cell Res Ther. 2020 Aug 8;11(1):345
pubmed: 32771052
Development. 2021 Sep 1;148(17):
pubmed: 34486650
Stem Cell Res Ther. 2019 Jan 3;10(1):1
pubmed: 30606242
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Front Cell Dev Biol. 2020 Jul 09;8:497
pubmed: 32742977
Stem Cells. 2019 Jul;37(7):855-864
pubmed: 30977255
J Transl Med. 2007 Nov 15;5:57
pubmed: 18005405
J Cell Mol Med. 2018 Mar;22(3):1627-1639
pubmed: 29278305
Stem Cell Res Ther. 2018 Feb 13;9(1):36
pubmed: 29433563
Hum Reprod Update. 2018 Nov 1;24(6):673-693
pubmed: 30239705
Stem Cell Res Ther. 2017 Jan 23;8(1):11
pubmed: 28114977
Stem Cell Res Ther. 2022 Jan 28;13(1):33
pubmed: 35090547
NPJ Regen Med. 2019 Dec 2;4:22
pubmed: 31815001
Hum Reprod. 2016 May;31(5):1087-96
pubmed: 27005892
iScience. 2021 Nov 22;24(12):103501
pubmed: 34917895
J Obstet Gynaecol Res. 2020 Nov;46(11):2347-2355
pubmed: 32856391
Hum Reprod Update. 2016 Mar-Apr;22(2):137-63
pubmed: 26552890
Sci Rep. 2021 Apr 8;11(1):7689
pubmed: 33833265
World J Stem Cells. 2020 May 26;12(5):368-380
pubmed: 32547685
Mater Today Bio. 2021 Feb 25;11:100101
pubmed: 34036261
Cell Stem Cell. 2011 Jun 3;8(6):618-28
pubmed: 21624806
PLoS One. 2014 May 12;9(5):e96662
pubmed: 24819371
FASEB J. 2022 Mar;36(3):e22193
pubmed: 35201635
Am J Transl Res. 2020 Sep 15;12(9):4941-4954
pubmed: 33042399
Acta Myol. 2007 Dec;26(3):176-8
pubmed: 18646568
Mol Biol Cell. 2007 May;18(5):1586-94
pubmed: 17314403
Int J Mol Sci. 2020 Aug 17;21(16):
pubmed: 32824511
Stem Cell Res Ther. 2021 Feb 12;12(1):130
pubmed: 33579355
Hum Reprod. 2016 Dec;31(12):2723-2729
pubmed: 27664218
Ann Transl Med. 2020 Feb;8(4):56
pubmed: 32175350
Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):
pubmed: 35169075

Auteurs

Satoshi Hosoya (S)

Center for Regenerative Medicine, National Center for Child Health and Development Research Institute, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato, Tokyo, 105-8461, Japan.
Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.

Ryo Yokomizo (R)

Center for Regenerative Medicine, National Center for Child Health and Development Research Institute, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato, Tokyo, 105-8461, Japan.
Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.

Harue Kishigami (H)

Center for Regenerative Medicine, National Center for Child Health and Development Research Institute, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.

Yukiko Fujiki (Y)

Center for Regenerative Medicine, National Center for Child Health and Development Research Institute, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.

Erika Kaneko (E)

Division of Reproductive Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.

Mitsuyoshi Amita (M)

Division of Reproductive Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.

Takakazu Saito (T)

Division of Reproductive Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.

Hiroshi Kishi (H)

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato, Tokyo, 105-8461, Japan.

Haruhiko Sago (H)

Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan.

Aikou Okamoto (A)

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato, Tokyo, 105-8461, Japan.

Akihiro Umezawa (A)

Center for Regenerative Medicine, National Center for Child Health and Development Research Institute, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan. umezawa@1985.jukuin.keio.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Novel therapeutic strategies for injured...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Novel therapeutic strategies for injured...
questionsmedicales.fr › Appareil urogénital › Système génital › Système génital de la femme › Utérus › Endomètre › Novel therapeutic strategies for injured...
questionsmedicales.fr › Maladies urogénitales › Maladies génitales › Infertilité › Novel therapeutic strategies for injured...
questionsmedicales.fr › Appareil urogénital › Système génital › Système génital de la femme › Utérus › Novel therapeutic strategies for injured...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Fécondité › Novel therapeutic strategies for injured...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Cycle menstruel › Menstruation › Novel therapeutic strategies for injured...